
Hologic, Inc. (HOLX)
65.45 USD -7.35 (-10.10%) Volume: 8.13M
Hologic, Inc.’s stock price is currently at 65.45 USD, experiencing a substantial drop of -10.10% in this trading session with a trading volume of 8.13M. Despite the daily fluctuations, the stock has seen a year-to-date decline of -8.70%, indicating a bearish trend for HOLX.
Latest developments on Hologic, Inc.
Hologic Inc reported mixed results in their fiscal Q1 earnings, with strong growth in diagnostics offset by a decline in breast health. Despite beating EPS estimates at $0.8, the company faced challenges with dismal sales guidance for 2025, causing their stock to fall. This retreat in bottom line performance was further compounded by a revenue dip following a drop in demand and supply challenges. Despite these setbacks, Hologic remains focused on tackling women’s health disparities with innovative solutions like the Hologic Mia Keeys. Analysts at UBS adjusted the price target on Hologic to $80 from $84, maintaining a neutral rating amidst these developments. With a 0.9% increase in revenue in Q1 2025, Hologic continues to navigate the evolving healthcare landscape as they announce the end of life for the Fluoroscan InSight FD Mini C-Arm.
Hologic, Inc. on Smartkarma
Analysts at Baptista Research on Smartkarma have been closely following Hologic Inc, a company that recently announced its financial results for the fourth quarter and fiscal year 2024. The company showed strengths and challenges, with a 4.2% increase in total revenue to $987.9 million in the fourth quarter. Organic revenue growth, excluding COVID-related sales, was at 5%, and non-GAAP earnings per share (EPS) grew by 13.5% to $1.01. The research report titled “Hologic Inc.: Expanding Diagnostic Assay Portfolio For A Competitive Edge! – Major Drivers” provides insights into the company’s performance.
Another report by Baptista Research on Smartkarma focuses on Hologic Inc‘s strategic efficiency in the post-pandemic market. The company had a strong third quarter in fiscal 2024, reporting total revenue of $1.01 billion and a non-GAAP earnings per share of $1.06, surpassing their guidance predictions. This marked a return to revenue growth with a 3.1% increase compared to the previous year, indicating a solid recovery trajectory after challenges posed by COVID-19 and global disruptions like the chip shortage. The report titled “Hologic Inc.: Breast Health Innovations” highlights the company’s resilience and innovation in the healthcare sector.
A look at Hologic, Inc. Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Hologic Inc has a mixed long-term outlook. While the company scores well in terms of value, growth, and momentum, its resilience and dividend scores are lower. This suggests that Hologic Inc may have strong potential for growth and value appreciation in the future, but investors should be aware of the lower resilience and dividend payouts.
Hologic, Inc. is a developer, manufacturer, and supplier of premium diagnostic products, medical imaging systems, and surgical products. The company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a mixed outlook based on the Smartkarma Smart Scores, investors may want to consider the company’s strengths in value, growth, and momentum, while also taking into account its lower scores in resilience and dividend payouts.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars